These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 18793112)

  • 1. Off-label use of stents: bare-metal versus drug-eluting stents.
    Girod JP; Mulukutla SR; Marroquin OC
    Expert Rev Cardiovasc Ther; 2008 Sep; 6(8):1095-106. PubMed ID: 18793112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies.
    Kirtane AJ; Gupta A; Iyengar S; Moses JW; Leon MB; Applegate R; Brodie B; Hannan E; Harjai K; Jensen LO; Park SJ; Perry R; Racz M; Saia F; Tu JV; Waksman R; Lansky AJ; Mehran R; Stone GW
    Circulation; 2009 Jun; 119(25):3198-206. PubMed ID: 19528338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of "off-label" utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention.
    Roy P; Buch AN; Javaid A; Okabe T; Raya V; Pinto Slottow TL; Steinberg DH; Smith K; Xue Z; Gevorkian N; Satler LF; Kent KM; Suddath WO; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Feb; 101(3):293-9. PubMed ID: 18237587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes following drug-eluting versus bare metal stent implantation for lesion subsets excluded from pivotal clinical trials: findings from the GHOST Study (Guthrie Health System Off-Label StenT Study).
    Harjai KJ; Orshaw P; Shenoy C; Acharji S; Sporn D; Aboufares A; Stapleton D
    J Interv Cardiol; 2008 Aug; 21(4):315-24. PubMed ID: 18754967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of long-term outcomes of bare metal or drug-eluting stent implantation in standard versus off-label coronary narrowings.
    Harjai KJ; Orshaw P; Boura J; Sporn D
    Am J Cardiol; 2009 Jun; 103(11):1537-45. PubMed ID: 19463512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of drug-eluting stents: on-label and off-label perspectives.
    Weisz G; Stone GW
    Rev Cardiovasc Med; 2008; 9(1):46-61. PubMed ID: 18418309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications.
    Qasim A; Cosgrave J; Latib A; Colombo A
    Am J Cardiol; 2007 Dec; 100(11):1619-24. PubMed ID: 18036358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of drug-eluting versus bare-metal stenting used according to on- and off-label criteria.
    Carlsson J; James SK; Lindbäck J; Scherstén F; Nilsson T; Stenestrand U; Lagerqvist B;
    J Am Coll Cardiol; 2009 Apr; 53(16):1389-98. PubMed ID: 19371822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications.
    Ko DT; Chiu M; Guo H; Austin PC; Goeree R; Cohen E; Labinaz M; Tu JV
    J Am Coll Cardiol; 2009 May; 53(19):1773-82. PubMed ID: 19422984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug-eluting stents for diabetic patients. A critical appraisal of the currently available data from randomized trials].
    Silber S; Herdeg C
    Herz; 2008 Apr; 33(3):196-205. PubMed ID: 18568314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-eluting stents versus bare-metal stents for off-label indications: a propensity score-matched outcome study.
    Austin D; Oldroyd KG; McConnachie A; Slack R; Eteiba H; Flapan AD; Jennings KP; Northcote RJ; Pell AC; Starkey IR; Pell JP
    Circ Cardiovasc Interv; 2008 Aug; 1(1):45-52. PubMed ID: 20031654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents.
    Kim YH; Park DW; Lee SW; Yun SC; Lee CW; Hong MK; Park SW; Seung KB; Gwon HC; Jeong MH; Jang Y; Kim HS; Seong IW; Park HS; Ahn T; Chae IH; Tahk SJ; Chung WS; Park SJ;
    Circulation; 2009 Aug; 120(5):400-7. PubMed ID: 19620506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials.
    Kirtane AJ; Ellis SG; Dawkins KD; Colombo A; Grube E; Popma JJ; Fahy M; Leon MB; Moses JW; Mehran R; Stone GW
    J Am Coll Cardiol; 2008 Feb; 51(7):708-15. PubMed ID: 18279734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model.
    Garg P; Cohen DJ; Gaziano T; Mauri L
    J Am Coll Cardiol; 2008 May; 51(19):1844-53. PubMed ID: 18466798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-eluting stents in primary percutaneous coronary intervention for ST-elevation myocardial infarction: an up-to-date review of the literature.
    Ehdaie A; Lee MS
    Minerva Cardioangiol; 2009 Oct; 57(5):645-55. PubMed ID: 19838154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
    Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the landscape of stent thrombosis: the drug-eluting versus bare-metal stent controversy.
    Rizik DG; Klassen KJ
    Am J Cardiol; 2008 Nov; 102(9 Suppl):4J-11J. PubMed ID: 18928786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting stents: a critique.
    Melikian N; Wijns W
    Heart; 2008 Feb; 94(2):145-52. PubMed ID: 18195121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.